Related Experiment Video

Updated: Aug 18, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis

Adam Gordon1, Catriona A McLean, John S Pedersen

  • 1Department of Gastroenterology, The Alfred Hospital, Commercial Road, Prahran 3181, Vic., Australia.

Journal of Hepatology
|May 7, 2005
PubMed

Insights

Hepatic steatosis is common in chronic hepatitis B and C. Predictors include waist circumference, glucose, C-peptide, and hepatitis C genotype 3, impacting fibrosis progression.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Viral Hepatitis Research

Background:

  • Hepatic steatosis frequently co-occurs with chronic hepatitis B (CHB) and chronic hepatitis C (CHC).
  • Understanding steatosis predictors is crucial for managing liver disease progression in these patients.

Purpose of the Study:

  • To identify predictors of hepatic steatosis in CHB and CHC patients.
  • To evaluate the impact of these predictors on liver inflammation and fibrosis.

Main Methods:

  • Retrospective analysis of liver biopsy data from 91 CHB and CHC patients.
  • Histological assessment by blinded hepatopathologists.

Main Results:

  • Waist circumference, glucose, C-peptide, and CHC genotype 3 predicted steatosis severity.
  • Alcohol intake and age predicted hepatic fibrosis.
  • Steatosis correlated with fibrosis progression in non-3 CHC genotypes.

Conclusions:

  • Hepatic steatosis in CHB/CHC is linked to metabolic factors and CHC genotype.
  • Steatosis severity may influence fibrosis progression, particularly in CHC genotype non-3.
Abstract

More Related Videos

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...